Enzon CEO is former Ilex head
Executive Summary
Former Ilex CEO Jeffrey Buchalter joins Enzon as chief executive. Buchalter will continue to serve as chairman of Enzon's board of directors, a role he has held since September. Genzyme completed its acquisition of Ilex Dec. 21. Buchalter previously held positions at Pharmacia, Wyeth, and Schering-Plough...
You may also be interested in...
Enzon CFO
Enzon promotes Exec VP-Strategic Planning & Corporate Communications Craig Tooman to CFO. Before joining Enzon in January, Tooman served as Ilex' senior VP-strategic planning & corporate communications, where he was involved in the company's sale to Genzyme. Tooman's former boss, former Ilex CEO Jeffrey Buchalter, is CEO of Enzon (1"The Pink Sheet" Jan. 3, 2005, In Brief)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.